Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration

Circulation

Volumn 112, Issue 22, 2005, Pages 3495-3500

  Straczek, Céline ^a   Oger, Emmanuel ^b   De Jonage Canonico, Marianne Beau Yon ^a   Plu Bureau, Geneviève ^a,c   Conard, Jacqueline ^c   Meyer, Guy ^d   Alhenc Gelas, Martine ^e   Lévesque, Hervé ^f   Trillot, Nathalie ^g   Barrellier, Marie Thérèse ^h   Wahl, Denis ^a,i   Emmerich, Joseph ^d,e   Scarabin, Pierre Yves ^a  

^a INSERM   (France)

^b SERVICE DE RHUMATOLOGIE   (France)

^c HÔTEL DIEU   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f ROUEN UNIVERSITY HOSPITAL   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h CHU CÔTE DE NACRE   (France)

ⁱ CHU NANCY BRABOIS   (France)

Author keywords

Embolism; Epidemiology; Genetics; Hormones; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; ESTRADIOL; ESTROGEN; GESTAGEN; PROTHROMBIN; BLOOD CLOTTING FACTOR 5;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FRANCE; GENETIC RISK; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MUTATION; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOSIS; VENOUS THROMBOEMBOLISM; CLINICAL TRIAL; DRUG ADMINISTRATION ROUTE; GENETICS; HORMONE SUBSTITUTION; MIDDLE AGED; MISSENSE MUTATION; MULTICENTER STUDY; PHYSIOLOGY; RISK FACTOR; THROMBOEMBOLISM; THROMBOPHILIA; VEIN THROMBOSIS;

AGED; CASE-CONTROL STUDIES; DRUG ADMINISTRATION ROUTES; ESTROGENS; FACTOR V; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; MUTATION; MUTATION, MISSENSE; POSTMENOPAUSE; PROTHROMBIN; RISK FACTORS; THROMBOEMBOLISM; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 33644876850     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.565556     Document Type: Article

References (17)

1. Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med. 2004;164:1965-1976.
2. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003;362:428-432.
3. Bertina RM. Genetic aspects of venous thrombosis. Eur J Obstet Gynecol Reprod Biol. 2001;95:189-192.
4. Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T, Arruda V, Hillarp A, Reny UL. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism: pooled analysis of 8 case-control studies including 2310 cases and 3204 controls: Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost. 2001;86:809-816.
5. Herrington DM, Vittinghoff E, Howard TD, Major DA, Owen J, Reboussin DM, Bowden D, Bittner V, Simon JA, Grady D, Hulley SB. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol 2002;22:1012-1017.
6. Rosendaal FR, Vessey M, Rumley A, Daly E, Woodward M, Helmerhorst FM, Lowe GD. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol. 2002;116:851-854.
7. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, Sidney S, Rosendaal FR, for the Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292:1573-1580.
8. Happich D, Schwaab R, Hanfland P, Hoernschemeyer D. Allelic discrimination of factor V Leiden using a 5′ nuclease assay. Thromb Haemost. 1999;82:1294-1296.
9. Happich D, Madlener K, Schwaab R, Hanfland P, Potzsch B. Application of the TaqMan-PCR for genotyping of the prothrombin G20210A mutation and of the thermolabile methylenetetrahydrofolate reductase mutation. Thromb Haemost. 2000;84:144-145.
10. Guo SW, Thompson EA. Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics. 1992;48:361-372.
11. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol. 2002;22:201-210.
12. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: a randomized controlled trial. Arterioscler Thromb Vasc Biol. 1997;17:3071-3078.
13. Conard J, Samama M, Basdevant A, Guy-Grand B, de Lignieres B. Differential AT III-response to oral and parenteral administration of 17 beta-estradiol. Thromb Haemost. 1983;49:252.
14. Hoibraaten E, Mowinckel MC, de Ronde H, Bertina RM, Sandset PM. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. Br J Haematol. 2001;115:415-420.
15. Post MS, Christella M, Thomassen LG, van der Mooren MJ, van Baal WM, Rosing J, Kenemans P, Stehouwer CD. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol. 2003;23:1116-1121.
16. Oger E, Alhenc-Gelas M, Lacut K, Blouch MT, Roudaut N, Kerlan V, Collet M, Abgrall JF, Aiach M, Scarabin PY, Mottier D, for the SARAH Investigators. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol. 2003;23:1671-1676.
17. Jick H, Vessey MP. Case-control studies in the evaluation of drug-induced illness. Am J Epidemiol. 1978;107:1-7.